Acne Cure News

Nodular Archives

Consensus-Based Acne Classification System and Treatment Algorithm for Spain

Acne is a chronic inflammatory disease whose psychosocial effects can greatly impair quality of life. Various scales are used to classify the severity of acne, and several treatment algorithms are currently applied: no consensus on a common scale or treatment guidelines has been reached. A group of Spanish experts therefore met to identify a scale the majority could accept as the most appropriate for classifying severity and treating accordingly.

Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study

Hidradenitis Suppurativa (HS), also known as acne inversa, is a painful, chronic, debilitating, inflammatory skin disease and has shown response to anti-TNF-α therapy. Efficacy and safety of the anti-TNF-α agent, adalimumab, was assessed in a post hoc analysis of women from the first 16 weeks of a phase 2 study of men and women with HS.

Comparison of TLR-2, TLR-4, and antimicrobial peptide levels in different lesions of acne vulgaris

Recent studies have shown that tolls like receptors (TLRs) and antimicrobial peptides (hBD-1, cathelicidin) play an important role in the pathogenesis of acne vulgaris (AV). Objective: To evaluate and report the expression of TLR-2, TLR-4, hBD-1 and cathelicidin in different regions of skin in AV.

BioPharmX begins enrollment in phase 2b trial of BPX-01 for acne

BioPharmX announced it has begun enrollment of patients in its phase 2b clinical trial measuring the efficacy and safety of BPX-10 for treating acne vulgaris. The OPAL study is a 12-week multi-center, double-blind vehicle-controlled study of BPX-01, a fully solubilized topical minocycline gel that delivers the drug directly to the acne source while avoiding systemic exposure.

Is hormonal treatment still an option in acne today?

This review summarizes the latest information on hormonal therapies including: combined oral contraceptives; anti-androgens, such as cyproterone acetate, spironolactone and flutamide; low-dose glucocorticoids and gonadotropin-releasing hormone agonists.